Abstract: Methods for detecting and treating prostate and lung cancer are disclosed In practicing the method, a subject sample is assayed for GPR110 protein or its RNA transcript, and the GPR110 or transcript level observed is used in determining whether the subject has an elevated GPR110 level associated with prostate or lung cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPR110 related immunotherapy agents.
Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.
Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.